微调CAR T细胞的抗原敏感性:新兴的策略和当前的挑战
Dennis Christoph Harrer1,2, Sin-Syue Li2,3, Marcell Kaljanac2
1Deptartment of Hematology and Internal Oncology, University Hospital Regensburg, Regensburg, Germany.
Frontiers in immunology
|December 13, 2023
概括
化学抗原受体 (CAR) T细胞疗法因抗原损失和T细胞耗尽而面临复发. 新的CAR设计旨在提高对低抗原癌症的敏感性,提高疗效并降低复发风险.
科学领域:
- 免疫治疗是一种免疫疗法.
- 在瘤学瘤学.
- 细胞疗法细胞疗法
背景情况:
- 化学抗原受体 (CAR) T细胞被批准用于B细胞恶性瘤,这代表了免疫治疗的重大进展.
- 癌症T细胞治疗的成功受到疾病复发的限制,通常是由癌细胞上向抗原下调引起的.
- 在CAR激活值以下的T细胞耗尽和抗原损失使CAR T细胞治疗无效.
研究的目的:
- 为了应对抗原低癌症患者中CAR T细胞治疗复发的挑战.
- 探索增强CAR T细胞对低密度抗原敏感性的策略.
- 在CAR T细胞疗法中提高治疗效果和减少瘤复发.
主要方法:
- 审查目前的CAR T细胞设计策略.
- 讨论针对低抗原癌细胞的挑战.
- 探索增加CAR灵敏度的方法.
主要成果:
- 抗原下调是CAR T细胞治疗失败的主要原因.
- 癌细胞的抗原密度低,需要提高CAR敏感度.
- 目前正在制定策略,以克服抗原逃逸和T细胞枯竭.
结论:
- 增加CAR T细胞敏感性对于治疗低抗原瘤至关重要.
- 改进的CAR设计可以提高治疗疗效,并最大限度地减少复发.
- 需要进一步的研究来优化CAR T细胞治疗各种恶性瘤,包括固体瘤.
相关概念视频
01:27Tumor Immunotherapy
529
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
529
01:22T Cell Activation and Clonal Selection
741
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
741